369 completed, 58 unknown, 34 terminated, 18 withdrawn. 166 Phase 2, 130 Phase 4, 118 Phase 3, 41 Phase 1, 22 Not applicable.
Follow peginterferon alfa-2a: new trials by email Literature Review of peginterferon alfa-2a trials Research Report on peginterferon alfa-2a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-15 |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma DOC1021, Tumor resection, pIFN (peginterferon alfa-2a) - Refractory Melanoma | Phase 1 / Phase 2 | Recruiting | Diakonos Oncology Corporation | 35 | 2026-04-06 | 2026-09-09 |
| A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B IB-001, Placebo, Peginterferon Alfa-2A - Chronic Hepatitis B Virus Infection | Phase 1 | Recruiting | IntegerBio | 88 | 2026-02-20 | 2026-09-28 |
| VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B VIR-2218 and peginterferon alfa-2a - Chronic Hepatitis B | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 12 | 2025-01-31 | 2026-10-05 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants BMS-986465, Placebo, Pegasys - Healthy Participants | Phase 1 | Terminated | Bristol-Myers Squibb | 267 | 2024-01-29 | 2025-02-06 |
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression Pegasys, Saline - Colon Cancer | Phase 2 | Unknown | Zealand University Hospital | 68 | 2023-08-14 | 2023-08-18 |
| AlloHCT With PegINFa for Myelofibrosis Pegylated interferon alpha2a - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 18 | 2023-08-02 | 2026-10-13 |
| Cemiplimab/Peg-Interferon-α in Advanced CSCC Cemiplimab-Rwlc, PEG-IFN alfa-2a - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Withdrawn | Baptist Health South Florida | 2023-07-01 | 2023-08-09 | |
| HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV Bulevirtide - Hepatitis D | Unknown | University of Athens | 80 | 2023-05-01 | 2023-07-03 | |
| A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets - Chronic Hepatitis B | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 8 | 2022-08-23 | 2024-07-15 |
| A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg - Hepatitis B, Chronic | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 96 | 2021-06-18 | 2025-01-27 |
| Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC Anti-PD-1/PD-L1, PEG-Interferon Alfa - Hepatocellular Carcinoma | Unknown | Shanghai Zhongshan Hospital | 15 | 2021-06-15 | 2022-03-31 | |
| A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531) - Hepatitis B, Chronic | Phase 2 | Completed | Hoffmann-La Roche | 281 | 2020-07-05 | 2025-09-19 |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection VIR-2218, pegylated interferon-alfa 2a - Chronic Hepatitis B | Phase 2 | Completed | Vir Biotechnology, Inc. | 84 | 2020-07-03 | 2026-04-16 |
| A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir EYP001a, Entecavir, Pegylated interferon alpha2a - Hepatitis B, Chronic | Phase 2 | Completed | Enyo Pharma | 20 | 2020-05-25 | 2022-08-25 |
| Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis Tenofovir Disoproxil Fumarate, PEG-Interferon alfa 2a - Hepatitis B, Liver Fibrosis | Not applicable | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 186 | 2019-11-06 | 2020-01-22 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta | Phase 2 | Completed | Gilead Sciences | 175 | 2019-05-31 | 2024-10-08 |
| Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis Tenofovir Disoproxil Fumarate, Peginterferon Alfa-2a, Peginterferon Alfa-2b - Hepatitis B, Liver Fibrosis | Not applicable | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 120 | 2019-02-01 | 2019-04-19 |
Showing 20 of 485. Sign in to see all of them.
Hepatitis C, Chronic (202) · Hepatitis C (150) · Hepatitis B, Chronic (92) · Hepatitis B (32) · HIV Infections (25) · Hepatitis (14) · Liver Cirrhosis (9) · Carcinoma, Hepatocellular (6) · Fibrosis (6) · Infections (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Liver Diseases (6) · Polycythemia Vera (6) · Thrombocythemia, Essential (6) · Acquired Immunodeficiency Syndrome (5)
Hoffmann-La Roche (108) · Bristol-Myers Squibb (26) · Gilead Sciences (17) · Vertex Pharmaceuticals Incorporated (16) · National Taiwan University Hospital (11) · Third Affiliated Hospital, Sun Yat-Sen University (11) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (10) · Merck Sharp & Dohme LLC (9) · Kaohsiung Medical University Chung-Ho Memorial Hospital (8) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Debiopharm International SA (7) · Beijing Ditan Hospital (6) · M.D. Anderson Cancer Center (6) · Xiamen Amoytop Biotech Co., Ltd. (6) · Janssen R&D Ireland (5)
United States (169) · France (93) · Germany (83) · Canada (68) · Spain (65) · China (64) · Puerto Rico (61) · United Kingdom (59) · Taiwan (58) · Italy (56) · Australia (53) · Poland (44) · Austria (38) · Belgium (38) · South Korea (36)
Chen-Hua Liu, MD (8) · Jia-Horng Kao, MD, PhD (6) · Ming-Lung Yu, MD, PhD (6) · Cheng-Chao Liang, MD (5) · Shih-Jer Hsu, MD (5) · Chih-Lin Lin, MD (4) · Ching-Sheng Hsu, MD (4) · Robert H. Hyland, DPhil (4)
PMID 25445400, PMID 24915612, PMID 19187608, PMID 21182232, PMID 22436845, PMID 23046671, PMID 23518903, PMID 24329937, PMID 25348661, PMID 37096802, PMID 15014185, PMID 19729084, PMID 22045673, PMID 23607594, PMID 24154738, PMID 24982088, PMID 25040192, PMID 25164700, PMID 25190434, PMID 26158171, PMID 26453773, PMID 26683763, PMID 26752189, PMID 30625297, PMID 30833068, PMID 34307188, PMID 39648559, PMID 40775758, PMID 10051494, PMID 12606735, PMID 14697813, PMID 15282352, PMID 15374882, PMID 15563253, PMID 15685543, PMID 15820563, PMID 15867490, PMID 15987917, PMID 16115185, PMID 16439867, PMID 16525137, PMID 16709929, PMID 16890601, PMID 17058240, PMID 17302380, PMID 17625124, PMID 17875007, PMID 18081737, PMID 18094378, PMID 18237873
2009 (8), 2004 (5), 2005 (4), 2008 (4), U01DK082843 (3), U01DK082864 (3), U01DK082871 (3), U01DK082874 (3), U01DK082944 (3), UL1TR000004 (3), 2014 (2), 2019 (2), M01RR000040 (2), P01CA108671 (2), P30DK050306 (2)